

Manx Biomed Conference

China Focus - China and the IOM: Potential
Alliances in health care and life sciences

6 December 2018



Isle of Man
Government

Reillys Ellan Vannin

Why China?

- World's second largest economy - first by 2032
- Largest overseas investor - \$20.8bn into UK in 2017 (\$9.2bn 2016)
- IOM strategy positioning - Gateway to UK/EU for Chinese 'Going global'



Biomed/Healthcare opportunities - IOM and China

- Dept for Enterprise has pursued a Chinese business strategy
- China's 13th 5 year Plan: theme is 'the land of opportunity' - plan to lead in innovation and entrepreneurship....
- Chinese alternative medicine is of growing interest to West
- IOM DFE has identified and targeted a number of Chinese biomed companies who are at various stages of interest/ involvement with IOM in terms of inbound investment eg:
- Xyz Large Chinese medical device manufacturer (inc.in IOM 2017)
- KB(raspberry neutraceuticals (establishing here 2019)
- JZMJ Mushrooms (visited July 2018)
- Dr Ning (various projects starting 2018)

Biomed/Healthcare opportunities - IOM and China (Cont.)

- Other Chinese biomed/healthcare companies who are at various stages of interest/discussion with IOM eg;
- Xyz Healthcare insurance
- ‘Care Family’ (medical graphene)
- AMK Medical
- Irish based Hemp project (with China links)
- Outbound investment/export to China opportunities (and market research)
- Regional MOUs for 2 way trade: eg Shanghai Municipal Commission of Commerce (signed April 2016)
- Connections - Special guest: Douglas (Tao) Dong, Chief Representative, Shanghai Invest, London

Biomed/Healthcare opportunities - IOM and China (Cont.)

Panel

- Mark Gledhill Project Manager, Biomed, Health and Life Sciences, DFE
- Steven Beevers Head of China Desk, DFE
- Douglas Dong Chief Representative Shanghai Invest, London
- Chris Eaton CEO, ILS World Group

DEPARTMENT FOR
ENTERPRISE



Isle of Man
Government
Reillys Ellan Vannin